Lyell Immunopharma, Inc. (LYEL) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.00K; Additional Paid in CapitalUSD $1.92B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-158.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.00K; Additional Paid in CapitalUSD $1.92B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-9.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.00K; Additional Paid in CapitalUSD $1.87B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $242.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.00K; Additional Paid in CapitalUSD $1.81B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $201.00K.
Lyell Immunopharma, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Additional Paid in Capital, Common Stock USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $2.00K | $1.92B | $-158.00K | $-1.69B | $233.81M | 3 month · $4.53M 6 month · $8.83M | (m) |
| 2026-03-31 | $0.00 | $2.00K | $1.92B | $-9.00K | $-1.64B | $273.67M | 3 month · $4.29M | (m) |
| 2025-12-31 | $0.00 | $2.00K | $1.87B | $242.00K | $-1.62B | $248.20M | 12 month · $41.83M | (m) |
| 2025-09-30 | $0.00 | $2.00K | $1.81B | $201.00K | $-1.48B | $329.12M | 3 month · $5.23M 9 month · $16.26M | (m) |
| 2025-06-30 | $0.00 | $1.00K | $1.74B | $57.00K | $-1.44B | $298.92M | 3 month · $5.00M 6 month · $11.03M | (m) |
| 2025-03-31 | $0.00 | $30.00K | $1.73B | $158.00K | $-1.40B | $336.52M | 3 month · $6.02M | (m) |
| 2024-12-31 | $0.00 | $1.00K | $1.73B | $291.00K | $-1.35B | $382.82M | 12 month · $33.14M | (m) |
| 2024-09-30 | $0.00 | $26.00K | $1.68B | $760.00K | $-1.15B | $530.70M | 3 month · $7.62M 9 month · $25.06M | (m) |
| 2024-06-30 | $0.00 | $26.00K | $1.68B | $-397.00K | $-1.11B | $566.50M | 3 month · $8.28M 6 month · $17.44M | (m) |
| 2024-03-31 | $0.00 | $25.00K | $1.67B | $-404.00K | $-1.06B | $603.16M | 3 month · $9.15M | (m) |
| 2023-12-31 | $0.00 | $25.00K | $1.66B | $-94.00K | $-1.00B | $654.95M | 12 month · $47.08M | (m) |
| 2023-09-30 | $0.00 | $25.00K | $1.65B | $-1.18M | $-949.18M | $697.57M | 3 month · $10.52M 9 month · $38.62M | (m) |
| 2023-06-30 | $0.00 | $25.00K | $1.64B | $-2.38M | $-898.33M | $736.86M | 3 month · $14.22M 6 month · $28.11M | (m) |
| 2023-03-31 | $0.00 | $25.00K | $1.62B | $-3.88M | $-834.44M | $783.83M | 3 month · $13.88M | (m) |
| 2022-12-31 | $0.00 | $25.00K | $1.61B | $-7.60M | $-767.48M | $833.25M | 12 month · $81.92M | (m) |
| 2022-09-30 | $0.00 | $25.00K | $1.59B | $-10.00M | $-759.08M | $820.03M | 3 month · $19.12M 9 month · $63.56M | (m) |
| 2022-06-30 | $0.00 | $25.00K | $1.57B | $-8.35M | $-688.83M | $868.04M | 3 month · $22.41M 6 month · $44.44M | (m) |
| 2022-03-31 | $0.00 | $25.00K | $1.54B | $-6.60M | $-652.51M | $881.25M | 3 month · $22.03M | (m) |
| 2021-12-31 | $0.00 | $24.00K | $1.52B | $-1.62M | $-584.36M | $929.79M | 12 month · $62.20M | (m) |
| 2021-09-30 | $0.00 | $24.00K | (m) | $-65.00K | $-500.66M | $986.47M | 3 month · $13.04M 9 month · $41.02M | $1.49B |
| 2021-06-30 | $0.00 | $24.00K | (m) | $73.00K | $-451.78M | $1.02B | 3 month · $15.25M 6 month · $27.98M | $1.47B |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | $-334.05M | 3 month · $12.73M | (m) |
| 2020-12-31 | $0.00 | $2.00K | $41.36M | $256.00K | $-334.14M | $-292.53M | 12 month · $33.26M | $41.36M |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $-266.64M | 3 month · $9.78M 9 month · $20.29M | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-240.11M | 3 month · $7.27M 6 month · $10.54M | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $-150.83M | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $-111.11M | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $850.00K | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |